Literature DB >> 16747549

Adenosine deaminase.

T Brady1.   

Abstract

Entities:  

Year:  1942        PMID： 16747549      PMCID： PMC1265723          DOI： 10.1042/bj0360478

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


× No keyword cloud information.
  6 in total

1.  Maleic acid as inhibitor of enzyme reactions induced by SH-compounds.

Authors:  E J Morgan; E Friedmann
Journal:  Biochem J       Date:  1938-05       Impact factor: 3.857

2.  On the Preparation of Collodion Membranes of Differential Permeability.

Authors:  W Brown
Journal:  Biochem J       Date:  1915-12       Impact factor: 3.857

3.  Carbonic anhydrase. Purification and nature of the enzyme.

Authors:  D Keilin; T Mann
Journal:  Biochem J       Date:  1940-09       Impact factor: 3.857

4.  The deaminases of adenosine and adenylic acid in blood and tissues.

Authors:  E J Conway; R Cooke
Journal:  Biochem J       Date:  1939-04       Impact factor: 3.857

5.  Isolation of adenine-desoxyriboside from thymusnucleic acid.

Authors:  T G Brady
Journal:  Biochem J       Date:  1941-09       Impact factor: 3.857

6.  The influence of thiol-groups in the activity of dehydrogenases.

Authors:  F G Hopkins; E J Morgan
Journal:  Biochem J       Date:  1938-03       Impact factor: 3.857
  6 in total
  13 in total

1.  The action of magnesium and calcium on the enzymic breakdown of certain adenine compounds.

Authors:  H B Stoner; H N Green
Journal:  Biochem J       Date:  1945       Impact factor: 3.857

2.  The effect of magnesium and calcium on the physiological properties of certain purine derivatives.

Authors:  M Bielschowsky; H N Green; H B Stoner
Journal:  J Physiol       Date:  1946-01-15       Impact factor: 5.182

3.  In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.

Authors:  J F Smyth; R C Young; D M Young
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

4.  Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.

Authors:  Kehinde Samuel Olaniyi; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-01       Impact factor: 3.000

Review 5.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Role of adenosine deaminase in lymphocyte proliferation.

Authors:  T Hovi; J F Smyth; A C Allison; S C Williams
Journal:  Clin Exp Immunol       Date:  1976-03       Impact factor: 4.330

8.  Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.

Authors:  Jae-Geun Lee; Dong Gu Kang; Jung Re Yu; Youngree Kim; Jinsoek Kim; Gwanpyo Koh; Daeho Lee
Journal:  Diabetes Metab J       Date:  2011-04-30       Impact factor: 5.376

9.  Adenosine deaminase activity in leukaemia.

Authors:  J F Smyth; K R Harrap
Journal:  Br J Cancer       Date:  1975-05       Impact factor: 7.640

10.  Adenosine deaminase activity modulation by some street drug: molecular docking simulation and experimental investigation.

Authors:  Massoud Amanlou; Ali-akbar Saboury; Roya Bazl; Mohammad Reza Ganjali; Shokoofeh Sheibani
Journal:  Daru       Date:  2014-05-02       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.